vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and First Bancorp, Inc (FNLC). Click either name above to swap in a different company.
First Bancorp, Inc is the larger business by last-quarter revenue ($25.8M vs $15.0M, roughly 1.7× CHAMPIONS ONCOLOGY, INC.). First Bancorp, Inc runs the higher net margin — 39.4% vs 1.8%, a 37.6% gap on every dollar of revenue. On growth, First Bancorp, Inc posted the faster year-over-year revenue change (17.5% vs 11.5%). First Bancorp, Inc produced more free cash flow last quarter ($34.6M vs $-2.0M). Over the past eight quarters, First Bancorp, Inc's revenue compounded faster (18.1% CAGR vs 11.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Patriot Bank, N.A. (PNBK) is the bank holding company for Stamford, Connecticut-based Patriot Bank NA, and is traded on NASDAQ as PNBK.
CSBR vs FNLC — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $25.8M |
| Net Profit | $268.0K | $10.2M |
| Gross Margin | 51.7% | — |
| Operating Margin | 1.2% | 48.1% |
| Net Margin | 1.8% | 39.4% |
| Revenue YoY | 11.5% | 17.5% |
| Net Profit YoY | -63.2% | 39.7% |
| EPS (diluted) | $0.02 | $0.91 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $25.8M | ||
| Q3 25 | $14.0M | $24.5M | ||
| Q2 25 | $12.4M | $22.5M | ||
| Q1 25 | $17.0M | $21.8M | ||
| Q4 24 | $13.5M | $22.0M | ||
| Q3 24 | $14.1M | $20.5M | ||
| Q2 24 | $14.0M | $19.2M | ||
| Q1 24 | $12.0M | $18.5M |
| Q4 25 | $268.0K | $10.2M | ||
| Q3 25 | $-436.0K | $9.1M | ||
| Q2 25 | $-1.8M | $8.1M | ||
| Q1 25 | $4.5M | $7.1M | ||
| Q4 24 | $728.0K | $7.3M | ||
| Q3 24 | $1.3M | $7.6M | ||
| Q2 24 | $-109.0K | $6.2M | ||
| Q1 24 | $-2.5M | $6.0M |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | 48.1% | ||
| Q3 25 | -3.8% | 45.2% | ||
| Q2 25 | -16.2% | 43.7% | ||
| Q1 25 | 26.4% | 39.3% | ||
| Q4 24 | 5.4% | 39.5% | ||
| Q3 24 | 9.5% | 44.6% | ||
| Q2 24 | -1.9% | 38.8% | ||
| Q1 24 | -21.4% | 39.3% |
| Q4 25 | 1.8% | 39.4% | ||
| Q3 25 | -3.1% | 37.0% | ||
| Q2 25 | -14.9% | 35.8% | ||
| Q1 25 | 26.4% | 32.5% | ||
| Q4 24 | 5.4% | 33.1% | ||
| Q3 24 | 9.3% | 36.9% | ||
| Q2 24 | -0.8% | 32.1% | ||
| Q1 24 | -21.1% | 32.5% |
| Q4 25 | $0.02 | $0.91 | ||
| Q3 25 | $-0.03 | $0.81 | ||
| Q2 25 | $-0.12 | $0.72 | ||
| Q1 25 | $0.31 | $0.63 | ||
| Q4 24 | $0.05 | $0.66 | ||
| Q3 24 | $0.09 | $0.68 | ||
| Q2 24 | $-0.01 | $0.55 | ||
| Q1 24 | $-0.19 | $0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | — |
| Total DebtLower is stronger | — | $95.5M |
| Stockholders' EquityBook value | $4.2M | $283.1M |
| Total Assets | $30.2M | $3.2B |
| Debt / EquityLower = less leverage | — | 0.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | — | ||
| Q3 25 | $10.3M | — | ||
| Q2 25 | $9.8M | — | ||
| Q1 25 | $3.2M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $2.9M | — | ||
| Q2 24 | $2.6M | — | ||
| Q1 24 | $4.5M | — |
| Q4 25 | — | $95.5M | ||
| Q3 25 | — | $95.5M | ||
| Q2 25 | — | $95.0M | ||
| Q1 25 | — | $70.0M | ||
| Q4 24 | — | $95.0M | ||
| Q3 24 | — | $95.0M | ||
| Q2 24 | — | $70.0M | ||
| Q1 24 | — | $70.0M |
| Q4 25 | $4.2M | $283.1M | ||
| Q3 25 | $3.5M | $274.6M | ||
| Q2 25 | $3.8M | $265.5M | ||
| Q1 25 | $5.5M | $259.7M | ||
| Q4 24 | $681.0K | $252.5M | ||
| Q3 24 | $-332.0K | $256.8M | ||
| Q2 24 | $-1.9M | $244.7M | ||
| Q1 24 | $-2.1M | $242.6M |
| Q4 25 | $30.2M | $3.2B | ||
| Q3 25 | $30.5M | $3.2B | ||
| Q2 25 | $32.3M | $3.2B | ||
| Q1 25 | $30.6M | $3.2B | ||
| Q4 24 | $25.2M | $3.2B | ||
| Q3 24 | $24.9M | $3.1B | ||
| Q2 24 | $26.1M | $3.1B | ||
| Q1 24 | $26.8M | $3.0B |
| Q4 25 | — | 0.34× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.36× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.38× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.29× | ||
| Q1 24 | — | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $37.8M |
| Free Cash FlowOCF − Capex | $-2.0M | $34.6M |
| FCF MarginFCF / Revenue | -13.1% | 133.9% |
| Capex IntensityCapex / Revenue | 1.6% | 12.5% |
| Cash ConversionOCF / Net Profit | -6.47× | 3.72× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $55.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $37.8M | ||
| Q3 25 | $600.0K | $12.9M | ||
| Q2 25 | $6.9M | $7.4M | ||
| Q1 25 | $490.0K | $2.2M | ||
| Q4 24 | $-283.0K | $26.0M | ||
| Q3 24 | $311.0K | $9.8M | ||
| Q2 24 | $-1.8M | $6.4M | ||
| Q1 24 | $-919.0K | $-1.5M |
| Q4 25 | $-2.0M | $34.6M | ||
| Q3 25 | $554.0K | $12.6M | ||
| Q2 25 | $6.6M | $7.2M | ||
| Q1 25 | $448.0K | $828.0K | ||
| Q4 24 | $-377.0K | $24.6M | ||
| Q3 24 | — | $9.6M | ||
| Q2 24 | $-1.8M | $6.3M | ||
| Q1 24 | $-1.0M | $-1.8M |
| Q4 25 | -13.1% | 133.9% | ||
| Q3 25 | 4.0% | 51.4% | ||
| Q2 25 | 53.5% | 32.1% | ||
| Q1 25 | 2.6% | 3.8% | ||
| Q4 24 | -2.8% | 111.7% | ||
| Q3 24 | — | 47.0% | ||
| Q2 24 | -13.0% | 32.9% | ||
| Q1 24 | -8.4% | -9.8% |
| Q4 25 | 1.6% | 12.5% | ||
| Q3 25 | 0.3% | 1.2% | ||
| Q2 25 | 2.0% | 0.6% | ||
| Q1 25 | 0.2% | 6.2% | ||
| Q4 24 | 0.7% | 6.7% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | 0.0% | 0.3% | ||
| Q1 24 | 0.8% | 1.8% |
| Q4 25 | -6.47× | 3.72× | ||
| Q3 25 | — | 1.42× | ||
| Q2 25 | — | 0.91× | ||
| Q1 25 | 0.11× | 0.31× | ||
| Q4 24 | -0.39× | 3.58× | ||
| Q3 24 | 0.24× | 1.29× | ||
| Q2 24 | — | 1.03× | ||
| Q1 24 | — | -0.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
FNLC
Segment breakdown not available.
